Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

Nearly one in four adults in Louisiana are considered obese, so it may not come as a surprise that our state also leads the ...

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

GLP-1 drugs like Wegovy (NVO) might help with weight loss, but they aren’t leading to lower health care costs yet, according to a new analysis of U.S. health insurance claims.

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be ...

The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...

Weight-loss jabs are not a quick fix for an “Instagram body”, the Health Secretary has warned. The medicines regulator has ...